Bank of America
IMNP

Bank of America’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Bank of America’s Portfolio IMNP Stock Details IMNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-23,514
Closed -$8K – 7531
2018
Q1 		$8K Buy
23,514
+1,920
+9% +$914 ﹤0.01% 6688
2017
Q4 		$12K Buy
+21,594
New +$20.5K ﹤0.01% 6581
2017
Q2 		– Sell
-2
Closed – – 7339
2017
Q1 		$0 Buy
+2
New +$7 ﹤0.01% 7447
2016
Q4 		– Sell
-2
Closed – – 7539
2016
Q3 		$0 Sell
2
-19
-90% -$140 ﹤0.01% 7526
2016
Q2 		$0 Buy
+21
New +$164 ﹤0.01% 7580

Other funds holding IMNP

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's IMNP Position: Q2 2018 in Review

Bank of America sold out of Immune Pharmaceuticals Inc. (IMNP) in Q2 2018, closing a stake of 23,514 shares — an estimated $8K sold.

Bank of America first reported a position in IMNP in Q2 2016 and held it in 5 quarters. The position peaked at $12K in Q4 2017. 13 funds tracked by Wall St. Rank hold IMNP as of Q2 2018.

  • Bank of America reported no remaining Immune Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • Bank of America sold 23,514 Immune Pharmaceuticals Inc. shares in Q2 2018, an estimated $8K.
  • Bank of America first reported a position in Immune Pharmaceuticals Inc. in Q2 2016 and held it in 5 quarters.
  • Bank of America's Immune Pharmaceuticals Inc. position peaked at $12K in Q4 2017.
  • 13 funds tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q2 2018.

Based on Bank of America's 13F filing for Q2 2018, filed 14 Aug 2018.